The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The prospect for RWD / RWE in the pharma sector is huge. The Co I referred to also has a Japanese collaboration Arctalis. Arcturus Therapeutics have just signed a great deal. But this article questions why they weren’t taken over. If nothing else, it does expose the potential out there in the pharma world.
https://www.evaluate.com/vantage/articles/news/deals-snippets/csl-stops-short-buying-arcturus
… By the way, that Co I was alluding to yesterday had quite an exciting announcement of their own completely unrelated
I agree entirely and only see name change as very positive. Something is happening here. It’s been almost 3 weeks since named changed at Co House. Nothing yet announced by the Company. The head of Real World Data and Engineering according to his LinkedIn info is working remotely out of Wurzburg Germany and this particular position has been held since Aug although he been with the Co for almost 4 years. We know from Snow that RWD and RWE is where the Cos focus will be. Any association with other Cos of an almost similar name at this time is pure speculation. But one thing is for sure Snow has made changes which hopefully we will hear about reasonably soon.
I’m not sure. There could be a Therapeutic reason ? I guess when they are ready, with any news flow, we will hear. However in the meantime the choice of new name does throw up one very interesting possibility that would allow immediate access to a listing in the U.S. BUT that is probably way off what’s going on here. But who knows.
You guys need to check with your brokers. The Co changed their name on 17 Oct at Companies House. What is very interesting is so far complete radio silence from the Co.
H&L changed the name over end of last week and emailed yesterday.
I wouldn’t be at all surprised that further news is to follow.
Anyone still holding unlisted Sensyne shares in their portfolio should have been notified by their broker about the name change to Arcturis Data Ltd and currently they still appear as 10p
https://pharmaphorum.com/news/phesi-launches-ai-driven-trial-accelerator-saving-7m-per-trial/
https://www.fiercebiotech.com/cro/phesi-touts-new-ai-platform-could-save-7m-p3-trial
But then again … maybe no coincidence at all.
Probably no more than coincidence with Arctoris.
https://www.barchart.com/story/news/10544722/arctoris-welcomes-on-board-globally-recognized-experts-in-machine-learning-chemical-computation-and-alzheimers-disease
It is quite a coincidence that the Co is renamed Arcturis Data Ltd when there is also Arctoris,
https://www.labiotech.eu/best-biotech/european-biotech-companies/
The potential is there.
GSK in patient data deal with American AI specialist to boost medicines pipeline
https://www.thetimes.co.uk/article/53237c04-4eee-11ed-b120-ca4f3ffbcdc5?shareToken=3d01df878bf046847ecfe4bdd0937c4a
We should get some update from the Co by some medium in the near future.
Sorry for mixing website.A very similar name im very similar business. I wasn’t paying proper attention.
Sorry forget that very similar name
It came up briefly. Looks like still in development
Wonder what plays lay ahead for the renamed Co.
Check Companies House …. We have a new name
After all, whilst one division was heavily loss making, one division had a £22m profit with a NAV of £80 odd million. Then of course we have the loan note debt to consider and it looks like conversion into shares may take place in January depending on the holders of these loan notes That’s when the dilution occurs